Terminal2 — Card #00: [Diagnosis Name]

S01 Everyone

What Is It

Congestive heart failure is a clinical syndrome — the final common pathway of multiple cardiac injuries. Understanding what it means at end-stage is the foundation of every hospice visit.

US Prevalence

~6.7M

Adults living with CHF in the US — the most common reason for hospitalization in patients over 65.^[1]

Annual Hospitalizations

>1M

CHF generates more hospitalizations than any other diagnosis. 30-day readmission rate approaches 25%, the highest of any condition tracked by CMS.^[2]

NYHA IV 1-yr Mortality

~50%

One-year mortality for NYHA Class IV exceeds most solid tumor cancers — yet median hospice enrollment for CHF patients remains under 30 days.^[3]

ICD in Stage D Patients

40–60%

Proportion of end-stage CHF patients with an active ICD in place. Device deactivation discussion is a clinical obligation, not an optional conversation.^[4]

Heart failure is not one disease. It is a syndrome — the final common pathway of multiple cardiac injuries including myocardial infarction, chronic hypertension, valvular disease, infiltrative cardiomyopathy, and genetic myopathies. The two dominant phenotypes are HFrEF (heart failure with reduced ejection fraction, EF <40%) and HFpEF (heart failure with preserved EF, EF ≥50%), with HFmrEF (EF 40–49%) occupying the middle range. HFrEF is driven by systolic dysfunction — the ventricle cannot contract adequately. HFpEF is driven by diastolic dysfunction — the ventricle cannot relax to fill adequately — and now accounts for more than half of all CHF cases in the US, disproportionately affecting older women and those with hypertension, obesity, and diabetes.^[5] The hospice team may encounter either phenotype or both simultaneously.

End-stage CHF in hospice — formally designated NYHA Class IV or ACC/AHA Stage D — is defined by the triad of refractory symptoms at rest or minimal exertion despite optimized medical therapy, recurrent hospitalizations with diminishing functional recovery, and exhausted compensatory neurohormonal mechanisms. The renin-angiotensin-aldosterone system and sympathetic nervous system, initially adaptive, become chronically activated and harmful — driving volume overload, progressive myocardial remodeling, arrhythmia, and organ failure. Cardiac cachexia, renal insufficiency, and hepatic congestion frequently complicate the picture. Unlike many malignancies, prognostication in CHF remains imprecise — patients can deteriorate suddenly, improve transiently with diuresis, and then deteriorate again — creating a deceptive clinical trajectory that delays hospice referral.^[6]

The ICD is the clinical elephant in every end-stage CHF room. Between 40–60% of Stage D CHF patients carry an implantable cardioverter-defibrillator. This device was placed to prevent sudden cardiac death — a reasonable goal when the patient had years to live. In the terminal phase, it prevents nothing except a peaceful death. The hospice team must identify device status on day one and initiate the deactivation conversation before it becomes a crisis.^[4]

Clinical Framing: Two Phenotypes, One Trajectory

Whether this patient has HFrEF (dilated, weak ventricle) or HFpEF (stiff, non-compliant ventricle), end-stage CHF presents the same way at the bedside: dyspnea at rest, orthopnea, massive peripheral edema, fatigue too profound to walk to the bathroom, and a prognosis that rivals Stage IV non-small cell lung cancer. The hospice team does not need a cardiology fellowship to manage this patient — but they do need to understand that diuretics, opioids for dyspnea, and a deactivated ICD are the three most important clinical tools in this house. Everything else is secondary.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"Every time I walk into a CHF home and see 'ICD — active' on the problem list with no documented deactivation conversation, I know what that family is going to go through when this man dies in front of them — the shocks, the screaming, the trauma that never goes away. The ICD is the first thing I check. Before the edema, before the oxygen sat, before the medications. If that device is still armed, that conversation has to happen today."

— Waldo, NP · Terminal2

S02 Clinician

How It's Diagnosed

Diagnostic workup, classification, and what to extract from hospice records. Most patients arrive with an established CHF diagnosis — this section helps you read the chart and understand what the numbers mean.

Diagnostic Workup

Guideline

Echocardiogram: Foundational study — documents ejection fraction, wall motion abnormalities, valvular disease (AS, MR), and filling pressures. Repeat echo after GDMT titration defines trajectory.^[7]
NT-proBNP / BNP: Biomarker of ventricular wall stress. NT-proBNP >1,000 pg/mL portends poor prognosis; >5,000 pg/mL in acute decompensation is associated with 6-month mortality >60%. Trending values more meaningful than any single result.^[8]
Chest X-ray: Cardiomegaly (cardiothoracic ratio >0.5), pulmonary vascular congestion (cephalization), Kerley B lines, bilateral pleural effusions — the radiographic footprint of volume overload.^[7]
ECG: LBBB (CRT eligibility), QRS prolongation, atrial fibrillation, ischemic changes, low voltage (consider cardiac amyloidosis if voltage low but echo shows thick walls).^[9]
Cardiac MRI: Gold standard for infiltrative disease — amyloidosis shows diffuse subendocardial late gadolinium enhancement. Identifies fibrosis extent and myocarditis.^[9]
Right heart catheterization: Hemodynamic profiling for advanced therapies (LVAD, transplant) — PCWP, cardiac output, PVR. Rarely performed in hospice setting but findings should be in records of Stage D patients.
Coronary angiography: Distinguishes ischemic from non-ischemic CM — critical for etiology.^[7]

What to Look for in Hospice Records

Expert

Ejection fraction and trend: EF at diagnosis vs. most recent echo. An EF that has worsened despite GDMT signals poor prognosis. A preserved EF does not mean mild disease.
Device history: ICD (brand, model, lead count), CRT-D vs. ICD-only, LVAD (model, pump speed, anticoagulation requirements), prior device infections or extraction history.
Deactivation status: Has ICD been deactivated? If CRT present, has pacing therapy been separately discussed? LVAD deactivation is a separate, more complex conversation requiring electrophysiology and ethics.
Etiology: Ischemic (prior MI, CAD) vs. non-ischemic (dilated CM, hypertensive, valvular, amyloidosis, peripartum). Ischemic CM often presents with renal insufficiency and angina overlay.
NYHA class trajectory: Class I–II baseline progressing to IV over months vs. years — rate of functional decline matters more than the class alone.
Hospitalization frequency: More than 2 hospitalizations in 6 months for decompensated CHF with declining recovery is a core hospice eligibility criterion.^[10]
Current GDMT status: Which of the four pillars are still running? What was stopped and why? Cessation due to hypotension, bradycardia, or renal failure signals hemodynamic fragility.
BNP and renal function trend: Rising BNP + declining GFR = cardiorenal syndrome — a marker of end-stage physiology.^[8]

Etiology of Cardiomyopathy

Review

Ischemic cardiomyopathy (~50%): Most common cause in the US — prior MI or diffuse CAD causing regional or global systolic dysfunction. Often co-exists with angina, renal insufficiency, peripheral vascular disease.
Non-ischemic dilated CM (~30%): Idiopathic, genetic, or inflammatory etiology. Younger patients, more abrupt onset, may have preserved outward appearance despite severe EF depression.
Hypertensive CM: Chronic pressure overload — initially HFpEF phenotype, may progress to systolic dysfunction. Most common substrate for HFpEF in older women.
Valvular CM: Severe aortic stenosis (pressure overload) or mitral regurgitation (volume overload) — distinct hemodynamic profiles and hospice device considerations (TAVR history?).
Cardiac amyloidosis (ATTR): Increasingly recognized, historically underdiagnosed. Wild-type ATTR-CM (senile) in men over 70; hereditary ATTR-CM (V122I variant in Black Americans). Low-voltage ECG + thick walls on echo is the classic clue.^[9]
Chemotherapy-induced CM: Anthracyclines (doxorubicin — dose-dependent, irreversible), trastuzumab (HER2-targeted, often reversible). Document prior oncologic therapy in all CHF patients.
Peripartum CM: Onset in last month of pregnancy or within 5 months postpartum. Variable recovery — hospice population represents those with incomplete recovery and progressive decline.

Classification Systems

Guideline

NYHA Functional Class: Class I (no limitation), II (slight limitation), III (marked limitation with ordinary activity), IV (symptoms at rest or minimal activity). Hospice patients are Class III–IV by definition. Captures symptoms, not structural disease.
ACC/AHA Stage: Stage A (at risk, no structural disease), B (structural disease, no symptoms), C (structural disease + current or prior symptoms), D (refractory HF requiring advanced intervention). Stage D = hospice-eligible. Does not regress — Stage D is permanent.^[7]
Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Profile: For LVAD candidates: Profile 1 (crash and burn) through 7 (advanced but stable). Profiles 1–3 require urgent intervention; relevant to LVAD deactivation conversations.
Seattle Heart Failure Model: Validated prognostic tool incorporating labs, medications, devices — estimates 1-, 2-, 3-year survival. Available online; useful for goals-of-care discussions.^[11]
MAGGIC Risk Score: Validated multivariate mortality risk calculator for CHF. Higher scores correlate with shorter survival — supports hospice referral documentation.^[11]

For Families: What the Echo Number Means

Most diagnostic work is already complete when a patient enrolls in hospice — the team is not starting from scratch. The key number families often ask about is the ejection fraction — the percentage of blood the heart pumps with each beat. A normal heart pumps 55–65%. Many of our patients' hearts pump 15–25%. That number helps the team understand how much reserve the heart has left, and it explains why walking across the room causes the same breathlessness that climbing a mountain would cause in a healthy person. The focus now is not on getting that number higher — it is on making every breath as comfortable as possible.

S03 Everyone

Causes & Risk Factors

Modifiable and hereditary risk factors for CHF. Relevant for answering "why did this happen?", identifying genetic risk in family members, and understanding the health equity dimensions of this disease.

Modifiable Risk Factors

Grade A

Coronary artery disease / prior MI: Most common cause of CHF in the US (~50% of all cases). Infarction destroys contractile myocardium, leaving permanent scar. Multiple MIs or large anterior MI = highest risk for HFrEF.^[12]
Hypertension: The most important modifiable risk factor for HFpEF. Decades of pressure overload cause concentric hypertrophy and diastolic stiffness. Affects over 70% of CHF patients.^[12]
Diabetes mellitus: Independent risk factor 2.5× — insulin resistance drives myocardial fibrosis, microvascular disease, and oxidative stress. SGLT2 inhibitors have altered this landscape significantly.^[13]
Obesity: Causes hemodynamic volume overload, adipose-mediated inflammation, and sleep apnea — independently doubles CHF risk. Contributes disproportionately to HFpEF.^[12]
Alcohol use disorder: Alcoholic cardiomyopathy is dose-dependent and potentially partially reversible with abstinence. Relevant to medication history and goals-of-care conversations.
Cardiotoxic chemotherapy: Anthracyclines (doxorubicin, daunorubicin) — cumulative dose-dependent, irreversible. Trastuzumab and pertuzumab — HER2-mediated, often reversible. Cyclophosphamide, tyrosine kinase inhibitors — increasingly recognized causes. Document oncologic history in every CHF patient.^[14]
Atrial fibrillation: Tachycardia-mediated cardiomyopathy — sustained rapid ventricular rate causes reversible systolic dysfunction. Also the most common arrhythmia complicating existing CHF, worsening hemodynamics acutely.
Obstructive sleep apnea: Causes nocturnal hypoxia, hypercapnia, and sympathetic surges — worsens existing CHF and is independently associated with worse outcomes.

Hereditary & Non-Modifiable

Grade B

Familial dilated cardiomyopathy: ~35% of non-ischemic DCM has identifiable genetic cause. Most common mutations: TTN (titin — ~25% of familial DCM), LMNA (lamin A/C — high arrhythmia risk), SCN5A, MYH7. Autosomal dominant inheritance — first-degree relatives warrant screening.^[15]
Hypertrophic cardiomyopathy (HCM): Autosomal dominant sarcomeric gene mutations (MYH7, MYBPC3 most common). Causes diastolic dysfunction, LVOT obstruction, arrhythmia. A small subset progresses to end-stage systolic dysfunction ("burnt-out HCM").^[15]
Cardiac amyloidosis — ATTR: Hereditary (hATTR) caused by pathogenic TTR gene variants — V122I/Val122Ile is a founder variant found in ~3.4% of African Americans and associated with late-onset cardiomyopathy. Wild-type (wtATTR) affects men over 65–70 without genetic mutation. Both cause restrictive cardiomyopathy with preserved or reduced EF and low ECG voltage relative to echo wall thickness.^[9]
Cardiac amyloidosis — AL: Plasma cell dyscrasia producing light chains that deposit in myocardium. Median survival without treatment 6 months; with treatment (daratumumab-based) significantly improved. Hospice-enrolled patients with AL amyloidosis have usually exhausted treatment options.^[9]
Age: CHF incidence doubles with each decade after 45. Physiologic cardiac aging reduces reserve, predisposing to HFpEF. The hospice CHF population is predominantly over 70.
Sex: Men have higher incidence overall; women have higher prevalence of HFpEF, present later in life, and have historically been under-enrolled in trials defining GDMT.^[12]
Race — Black Americans: Highest CHF incidence in the US, earliest age of onset (mean 10 years earlier than white counterparts), highest 5-year mortality, lowest rates of referral for advanced therapies. V122I TTR variant contributes to excess ATTR-CM burden. Disparities are systemic, not biological.^[16]

For Families: "Why Did This Happen?"

Families almost always ask this question — and they often carry guilt, especially if the patient had risk factors they knew about. The honest, compassionate answer: heart failure develops over many years from conditions that gradually weaken the heart, often without warning signs until the damage is done. High blood pressure, past heart attacks, diabetes — these are diseases in their own right, not moral failures. The patient did not bring this on themselves. The team's job now is not to relitigate the past — it is to make the time that remains as comfortable and meaningful as possible.

Clinician Note: Cardiac Amyloidosis Is Underdiagnosed

ATTR-CM — both wild-type and hereditary — may account for 13–16% of HFpEF in community-based populations, but was historically recognized only at autopsy. The diagnostic clue in the hospice chart: ECG showing low voltage (small QRS complexes) in a patient whose echo shows thick walls and a hyper-refractile myocardium. This combination should prompt review of prior nuclear bone scintigraphy (pyrophosphate scan) or cardiac MRI with late gadolinium enhancement. In Black American patients over 60 with CHF, always consider V122I hATTR-CM. Even at hospice enrollment, confirming the diagnosis matters for surviving family members — first-degree relatives of hATTR-CM carriers warrant genetic counseling and cascade screening. Tafamidis (ATTR-ACT trial, 2018) extends life significantly and the hospice team should document whether the patient was ever offered it.^[9]

Racial Disparities: A Systemic Failure, Not a Biological Fact

Black Americans develop CHF approximately 10 years earlier, have higher rates of hospitalization and in-hospital mortality, and are less likely to be referred for cardiac transplantation or LVAD evaluation compared to white patients with equivalent disease severity. These disparities persist after controlling for clinical variables — they are the product of structural racism in healthcare access, cardiovascular risk factor burden driven by neighborhood-level social determinants, and implicit bias in referral patterns. The hospice team cannot fix these upstream failures, but acknowledging them shapes how we listen to patients and families who may have experienced years of inadequate cardiac care before arriving on our service.^[16]

S04 Clinician Everyone

Treatments & Procedures

Standard CHF treatment trajectory — GDMT, device therapy, advanced options, and what remains appropriate in hospice. Understanding the full treatment history allows the team to interpret the patient's current state correctly.

CHF treatment in the modern era is defined by four-pillar Guideline-Directed Medical Therapy (GDMT) — a combination of neurohormonal blockade and metabolic modulation that has cumulatively reduced CHF mortality by 50–60% over three decades for HFrEF. Device therapy augments GDMT with arrhythmia prevention (ICD) and mechanical resynchronization (CRT). Advanced therapies — LVAD and cardiac transplantation — represent the ceiling for Stage D patients who remain eligible. By the time a patient reaches hospice, most of these interventions have either been applied and exhausted, or declined. The hospice team must know which treatments were used, which were stopped, and why — because the answers define the patient's hemodynamic reserve and guide comfort-focused management.^[7]

GDMT — The Four Pillars (HFrEF)

Grade A

ACE inhibitor / ARB / ARNI: ARNI (sacubitril/valsartan — PARADIGM-HF trial, 2014) reduced cardiovascular death or HF hospitalization by 20% vs. enalapril. Target dose: sacubitril 97mg/valsartan 103mg BID. Hospice implication: hypotension and renal insufficiency often force dose reduction or cessation in Stage D — document the attempt.^[17]
Beta-blocker: Carvedilol (COPERNICUS, US Carvedilol trials) and metoprolol succinate (MERIT-HF) — 35–65% relative risk reduction in mortality. Must be continued unless hemodynamically intolerable. Abrupt discontinuation in CHF risks rebound tachycardia and acute decompensation.^[18]
Mineralocorticoid receptor antagonist (MRA): Spironolactone (RALES trial — 30% mortality reduction in NYHA III–IV) and eplerenone (EMPHASIS-HF). Contraindicated when GFR <30 or K+ >5.0. Often first GDMT stopped in cardiorenal syndrome.^[19]
SGLT2 inhibitor: Dapagliflozin (DAPA-HF) and empagliflozin (EMPEROR-Reduced) reduce HF hospitalization and cardiovascular death in HFrEF regardless of diabetes status. Emerging benefit in HFpEF (EMPEROR-Preserved, DELIVER). May be continued in hospice in patients with adequate renal function — the osmotic diuresis provides a clinically useful adjunct to loop diuretics.^[13]

Device Therapy

Grade A

ICD (Implantable Cardioverter-Defibrillator): Indicated for EF ≤35% on optimal GDMT, expected meaningful survival >1 year. Prevents sudden cardiac death — does NOT improve symptoms, does NOT slow disease progression, does NOT prolong life in the terminal phase. In patients actively dying, the ICD will discharge repeatedly as fatal arrhythmias occur, causing pain and distress without clinical benefit. Deactivation is not physician-assisted death — it is removing an intervention that actively harms the patient.^[4]
CRT / CRT-D (Cardiac Resynchronization Therapy): Biventricular pacing for patients with EF ≤35% + LBBB + QRS ≥150ms. Improves symptoms, exercise capacity, and EF in ~70% of selected patients (responders). Pacing function can typically be left active — it does not cause harm at end of life. Defibrillation component should be assessed separately for deactivation.
LVAD (Left Ventricular Assist Device): Destination therapy for ineligible transplant patients or bridge to transplantation. Requires continuous AC power, anticoagulation (warfarin + aspirin), frequent pump adjustments. Deactivating an LVAD is a distinct, complex end-of-life decision — typically results in death within minutes to hours. Requires ethics consultation, palliative care, and device company support in most institutions.^[20]
Cardiac transplantation: Gold standard for eligible Stage D patients — median survival post-transplant exceeds 12 years. Only 3,500–4,000 transplants performed annually in the US. Patients on hospice are typically ineligible or have been delisted; document the reason (age, comorbidities, psychosocial criteria, or waitlist withdrawal at patient request).

Palliative Procedures — Still Appropriate in Hospice

Grade B

IV loop diuretic infusion: Furosemide or bumetanide IV — more reliably absorbed than oral in a congested gut. Can be administered at home via PICC line or at outpatient infusion center. DOSE trial (2011) showed high-dose strategy superior to low-dose for diuresis; continuous infusion vs. bolus dosing differs by institutional practice.^[21]
Palliative inotrope infusion (continuous): Dobutamine (beta-1 agonist) or milrinone (phosphodiesterase-3 inhibitor) — Class IIb, Grade B for refractory Stage D CHF. Provides hemodynamic support and symptom relief without expectation of survival benefit. Can be administered at home on hospice — this is a well-established and guideline-supported use in the comfort setting. Requires clear goals-of-care documentation.^[22]
Thoracentesis: For refractory pleural effusions causing dyspnea — typically bilateral in CHF. Provides significant immediate relief. Can be repeated. Tunneled PleurX catheter is an option for frequent recurrence in patients with adequate functional status to manage it.^[23]
Paracentesis: Hepatic congestion from right heart failure causes ascites — often significant (5–10L). Paracentesis provides immediate relief of abdominal distension, early satiety, and orthopnea from diaphragm elevation. Typically needs albumin replacement >5L drained. Can be repeated every 2–4 weeks in hospice-compatible protocol.^[23]
Ultrafiltration: Mechanical fluid removal for diuretic-resistant volume overload. CARRESS-HF trial showed no advantage over stepped-care diuresis in acute decompensation. Reserved for select refractory cases in hospice-adjacent settings — not standard home hospice.^[24]

What the Hospice Team Must Know on Day One

Expert

Device inventory: ICD? CRT-D or CRT-P? LVAD (model, speed, alarm settings)? Is there a wearable defibrillator (LifeVest)? Document and communicate to all team members, 24/7 on-call, and hospice aide.
Deactivation status: Has the ICD been deactivated? If not, who will facilitate — the cardiologist, the device company representative? Is there a device clinic contact? A magnet can be used emergently by any clinician to suspend ICD therapy — hospice should have this resource available.
Current GDMT and why agents were stopped: Which of the four pillars are still active? Hypotension stopping beta-blocker and ARNI signals hemodynamic decline. Worsening renal function stopping MRA and SGLT2 inhibitor signals cardiorenal syndrome. These are prognostic markers, not medication management failures.
Diuretic regimen and response: Current furosemide (or torsemide) dose; route (oral vs. IV); frequency; recent response. Weight-based diuresis protocol for home titration — a 2–3 lb weight gain over 24–48 hours should trigger additional diuretic dose per protocol.
Palliative inotrope status: Is the patient already on home dobutamine or milrinone? The hospice team must be able to manage the infusion pump, recognize complications (arrhythmia, infection at IV site, line dysfunction), and have a clear protocol for discontinuation.

S05 Clinician

When Therapy Makes Sense

Evidence-based criteria for continuing or initiating disease-directed therapy alongside palliative care. In CHF, many treatments are simultaneously disease-directed and comfort-directed — the distinction matters less than the goal.

The PAL-HF trial (Mentz et al., 2017) — a randomized controlled trial of palliative care integrated with standard CHF management — demonstrated that concurrent palliative care improved quality of life, anxiety, depression, and spiritual well-being in patients with advanced CHF without compromising survival or medical outcomes.^[25] This mirrors Temel's landmark 2010 work in NSCLC — palliative care does not accelerate death; it improves the dying. CHF is unique among non-malignant diseases because the treatments that provide the most symptom relief (diuretics, opioids, inotropes) are also the treatments that define comfort-focused care. The binary of "treatment vs. hospice" is a false one in this disease. The real question is: which treatments are aligned with the patient's goals, and which are prolonging suffering rather than life?

The following clinical scenarios represent situations where continuing or initiating specific therapy alongside palliative or hospice care provides meaningful symptom benefit or survival extension proportionate to its burden.^[26]

01

SGLT2 inhibitor continuation in ECOG 0–2 with adequate renal function (eGFR ≥25 mL/min): Dapagliflozin and empagliflozin provide a sustained osmotic diuretic effect that reduces HF hospitalization rates in both HFrEF and HFpEF. In patients still ambulatory with reasonable renal function, continuation reduces the diuretic burden, improves congestion management, and has a favorable safety profile. The pill burden is low (once daily) and cost is the primary barrier in the hospice setting — formulary access should be confirmed at enrollment.^[13]
02

Cardiac amyloidosis (ATTR-CM) with tafamidis eligibility: The ATTR-ACT trial (2018) demonstrated that tafamidis 80mg daily reduced all-cause mortality by 30% and cardiovascular hospitalizations by 32% in ATTR-CM with NYHA Class I–III over 30 months.^[27] Patients with confirmed ATTR-CM (hereditary or wild-type) who have not yet received tafamidis and remain NYHA Class I–III warrant urgent referral to cardiology for consideration — even in patients approaching hospice eligibility. The window for benefit is real. If the patient is NYHA IV or Stage D, the survival data are less clear, but symptom burden may still benefit. Document whether tafamidis was offered, accepted, or declined.^[27]
03

IV diuresis for acute decompensation — home or infusion center: A single patient who is hemodynamically compensated at baseline but experiencing an acute decompensation (5–10 lb weight gain, worsening dyspnea, orthopnea) may benefit dramatically from 1–3 days of IV furosemide (40–200mg IV daily or continuous infusion) with a return to baseline — without hospitalization. This is appropriate hospice management, not escalation. The DOSE trial established that higher-dose, IV diuresis is superior to low-dose oral strategies in acute decompensation. Home IV diuresis protocols should be pre-authorized at enrollment in appropriate patients.^[21]
04

Palliative inotrope infusion for refractory Stage D CHF: Continuous dobutamine (2–5 mcg/kg/min) or milrinone (0.1–0.375 mcg/kg/min) is explicitly listed in ACC/AHA guidelines as Class IIb for symptom palliation in Stage D CHF patients ineligible for advanced therapies.^[22] These patients are typically unable to tolerate neurohormonal therapy, have cardiac indices <2.0 L/min/m², and report dyspnea and fatigue at rest. The evidence consistently shows improved quality of life and functional capacity without survival benefit. Inotropes in this context are not "heroic measures" — they are palliative therapy equivalent to an opioid infusion for cancer dyspnea. The hospice clinical team must understand pump management, PICC care, and recognition of inotrope toxicity (atrial/ventricular arrhythmias, ischemia at high doses).
05

CRT optimization if present and suboptimally programmed: Cardiac resynchronization therapy reduces symptoms and improves EF in responders (~70% of appropriately selected patients). In a CHF hospice patient with a CRT device, if the device has never been optimized or the patient has gained weight since the last device clinic visit, a single CRT optimization visit (AV and VV delay programming) may provide meaningful symptomatic improvement with minimal burden. The cardiologist should be consulted — this is a one-time intervention, not ongoing therapy escalation.^[28]
06

Palliative TAVR or balloon aortic valvuloplasty for critical AS driving CHF: A small but meaningful subset of hospice-eligible CHF patients have critical aortic stenosis (AVA <1.0 cm², mean gradient >40 mmHg) as the primary driver of their heart failure — not myocardial disease. In patients with reasonable expected benefit, TAVR (transcatheter aortic valve replacement) is minimally invasive and may dramatically improve symptoms and survival. The STS/ACC TVT registry shows TAVR candidates at high surgical risk achieving meaningful 2-year survival gains. The decision requires cardiology, cardiac surgery, and palliative care input — but the hospice team should not reflexively assume TAVR is outside the scope of end-of-life care discussions.^[29]
07

Patient goals explicitly include symptom management with informed understanding of prognosis: A patient who understands their 6–12 month prognosis, declines hospitalization, and chooses to maximize comfort and time at home — but requests aggressive diuretic management, inotrope infusion, or SGLT2 therapy — is exercising informed autonomy. Their goals are fully compatible with hospice enrollment. The hospice team's role is to align the medical plan with those goals, not to enforce a narrower definition of "comfort care" that denies effective treatments.^[25]

S06 Clinician

When It Doesn't

Clinical criteria for recognizing when further disease-directed therapy causes harm without benefit. CHF is chronically under-referred to hospice — recognizing these thresholds is a clinical skill, not a defeat.

CHF patients are referred to hospice later than nearly any other diagnosis — a well-documented failure in the American healthcare system. The median length of hospice enrollment for CHF patients is under 30 days, compared to 60–90+ days for cancer diagnoses — even though the 1-year mortality of NYHA Class IV CHF exceeds that of most Stage III–IV solid tumors.^[3] The barrier is not malicious. It is a combination of prognostic uncertainty (CHF patients can improve with diuresis, obscuring true trajectory), physician reluctance to initiate the hospice conversation in a disease they have been managing for years, and patient hope anchored to device therapy and GDMT that has provided some benefit in the past. The result is that patients die in hospitals, in ICUs, with active ICDs, having never had a frank conversation about their prognosis. The hospice clinician — often the nurse practitioner or RN who enters the home — is frequently the first person to speak plainly. That conversation starts with knowing these criteria cold.^[30]

01

NYHA Class IV symptoms at rest or minimal activity despite optimal GDMT — ACC/AHA Stage D: The patient who cannot dress, shower, or walk to the bathroom without profound dyspnea and fatigue — and who has been on maximally tolerated GDMT for ≥3 months — meets the definition of end-stage CHF. "Optimal GDMT" means the four-pillar therapy has been attempted and either is running at target doses or was reduced/stopped due to hemodynamic intolerance. Stage D does not regress. This is a one-way door.^[7]
02

Recurrent hospitalizations (>2 in 6 months) with diminishing functional recovery: A patient hospitalized for decompensated CHF who returns to 90% of prior function is managing chronic disease. A patient hospitalized three times in six months who returns to 60%, then 40%, then 30% of prior function — and who can no longer live independently — is demonstrating the defining trajectory of end-stage CHF. CMS hospice eligibility criteria explicitly include this pattern. The hospice team should graph this trajectory in the chart.^[10]
03

Inability to tolerate neurohormonal therapy due to hemodynamic compromise: When systolic blood pressure chronically runs 80–90 mmHg, beta-blockers cause symptomatic bradycardia, and ARNI or ACE inhibitors precipitate acute kidney injury at any dose — the heart is operating at the floor of its hemodynamic reserve. The GDMT that extended life in earlier stages is now the medication that causes hypotension and falls. Documenting the attempted titration and the clinical reason for cessation is both prognostically informative and medically and legally appropriate for hospice enrollment.
04

Cardiac cachexia — unintentional weight loss >6% of body weight over 6 months not attributable to fluid shifts: Cardiac cachexia is a distinct pathophysiologic entity driven by chronic neurohormonal activation, gut congestion impairing absorption, and inflammatory cytokine elevation (TNF-α, IL-6). It is not correctable with nutritional supplementation. Muscle wasting and anorexia in this context are markers of terminal CHF physiology, not reversible malnutrition. Families should be counseled that eating more will not reverse this process — it reflects what the heart is doing to the body, not what nutrition can undo.^[31]
05

LVAD-ineligible or LVAD-declining patient with refractory Stage D CHF: When a patient has been evaluated for LVAD and determined ineligible (due to age, frailty, severe tricuspid regurgitation, fixed pulmonary hypertension, or severe non-cardiac comorbidity), or when the patient has declined LVAD after informed discussion, no further disease-directed cardiac intervention exists short of transplant. If transplant is also off the table, the patient has exhausted the ceiling of available therapy. Hospice enrollment at this juncture is not early — it is overdue.^[20]
06

Transplant-ineligible or delisted patient: Advanced age (>70–72 in most programs), significant non-cardiac organ dysfunction, obesity (BMI >35), active malignancy, severe frailty, or psychosocial criteria exclusion are common reasons for transplant ineligibility. A patient who has been listed and subsequently delisted due to clinical deterioration has, by definition, crossed into end-stage territory. This is a watershed moment that should trigger an explicit goals-of-care discussion and hospice referral if goals align.
07

Frequent ICD shocks without treatment benefit: An ICD discharging multiple times per week is not evidence of disease control — it is evidence of a dying heart generating fatal arrhythmias with increasing frequency. Each shock in a conscious patient is equivalent to a punch to the chest. Multiple shocks in the terminal phase constitute a medical emergency — not because the ICD is malfunctioning, but because it is functioning exactly as designed while the patient is dying. If ICD deactivation has not occurred and the patient is having breakthrough shocks, this requires same-day contact with the device clinic and an emergency magnet application.^[4]
08

Patient goals have shifted explicitly to comfort and home death: A fully informed patient who understands their prognosis, has had a frank discussion about the trajectory of their CHF, and who clearly articulates that they want to spend their remaining time at home — not in a hospital — without further resuscitation attempts, has made the clearest possible declaration of hospice appropriateness. Their NYHA class and ejection fraction are secondary to their autonomy. When a patient tells you "I'm done fighting and I want to die in my own bed," that is not a psychiatric symptom — it is clinical clarity, and the hospice team should honor it without delay.

ICD Deactivation: The Conversation That Cannot Wait

An active ICD in a terminally ill CHF patient is not a safety net — it is a trap. As the heart deteriorates, ventricular arrhythmias become more frequent, more sustained, and ultimately fatal. The ICD will fire — once, twice, ten times in the final hours — delivering 30–40 joules of electricity into a dying chest. Witnesses describe watching a loved one convulse repeatedly as they take their final breaths. Families carry this trauma for years. ICD deactivation is not physician-assisted death. It is not euthanasia. It is not withdrawal of care. It is the removal of an intervention that provides no benefit and causes significant harm in the terminal phase — ethically equivalent to stopping a ventilator or discontinuing dialysis. Every major medical society — AHA, HRS, ACC, NHPCO — explicitly supports ICD deactivation in this context. The hospice clinician must initiate this conversation at enrollment if the cardiologist has not. A magnet placed over the device generator immediately suspends ICD therapy without reprogramming — this should be available in every hospice clinical bag in patients with active ICDs.^[4]

The False Binary: "Treatment vs. Hospice" Does Not Exist in CHF

In oncology, "stopping chemotherapy" and "starting hospice" are often nearly synonymous — the disease-directed treatment and the comfort treatment are different drugs. In CHF, this binary does not exist. The treatments that improve CHF symptoms — furosemide, torsemide, metolazone, SGLT2 inhibitors, opioids for dyspnea, dobutamine infusions — are simultaneously comfort care and disease management. A hospice patient receiving IV furosemide and oral morphine for air hunger is receiving aggressive, evidence-based, guideline-supported palliative CHF care. The physician who tells a CHF patient "we've done everything we can" and refers to hospice without discussing ongoing diuretic optimization, inotrope infusion, or device deactivation has not completed the clinical handoff. The hospice team inherits not just the patient, but the responsibility to carry the best of what cardiology started — translated into the comfort-focused framework the patient has chosen.^[25]

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches specific to CHF in hospice. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical; D = expert opinion.

ICD Deactivation as Comfort Intervention

Grade A

Protocol: Cardiologist order or magnet protocol · Permanent deactivation preferred · Magnet as bridge

AHA, HRS, and ACC guidelines explicitly endorse ICD deactivation as ethically appropriate comfort care in terminal illness — not euthanasia, not withdrawal of life-sustaining treatment in any morally relevant sense.^[12] Active ICDs in dying CHF patients deliver painful, futile shocks in the final hours; studies show up to 31% of patients with implanted defibrillators receive shocks in the last 24 hours of life.^[37] Hospice NPs should initiate this conversation at enrollment — not wait for the cardiologist. Know your patient's device manufacturer. Have an ICD magnet at bedside as a temporary measure. Permanent deactivation via remote or in-office programming is the definitive solution.

Discuss at first hospice visit
Frame as removing a burden, not ending life
Document goals-of-care conversation in chart

Opioids for Refractory Dyspnea

Grade A

Morphine 2.5–5 mg PO/SQ q4h + PRN · Titrate to effect · No ceiling dose for comfort

Opioids are the strongest evidence-based intervention for dyspnea in advanced CHF and are chronically underprescribed in this population due to unfounded fears of respiratory depression at therapeutic doses.^[15]^[18] Morphine reduces the sensation of breathlessness through central mechanisms independent of oxygen saturation. A systematic review by Johnson et al. (2002) confirmed benefit for breathlessness in CHF without clinically significant respiratory compromise at comfort doses.^[18] Write morphine orders at enrollment for every Stage D CHF patient — do not wait for a crisis call. Low-dose scheduled morphine with robust PRN orders prevents escalating emergency visits.

Start low, titrate every 24–48 h to effect
SQ route equally effective when oral unavailable
Reteach patient and family at every visit

Fan Therapy for Dyspnea

Grade A

Protocol: Handheld or bedside fan directed at nose/mouth · Continuous as tolerated · Cost-free

Galbraith et al. (2010) demonstrated in an RCT that a handheld fan directed at the face significantly reduced dyspnea scores compared to fan directed away from the face in patients with advanced disease.^[17] The mechanism is trigeminal nerve stimulation via cool airflow, which modulates the central perception of breathlessness independent of oxygenation. In CHF patients with fluid-mediated dyspnea, fan therapy provides meaningful relief as a non-pharmacological adjunct and is appropriate alongside opioids. Cost is negligible. Teach every family member this intervention. A fan directed at the face in a dyspnea crisis is not futile care — it is evidence-based comfort.

Aim fan at nose and mouth, not ceiling
Works independently of oxygen level
More effective than supplemental O₂ in many CHF patients

Palliative Inotrope Infusion

Grade B

Dobutamine 2.5–10 mcg/kg/min IV continuous · Milrinone 0.1–0.375 mcg/kg/min IV · Home or inpatient

ACC/AHA guidelines designate palliative inotrope infusion as Class IIb for refractory Stage D CHF when the goal is symptom relief rather than survival prolongation.^[3]^[42] Dobutamine and milrinone can dramatically reduce dyspnea and fatigue in patients who have exhausted all oral therapies and cannot tolerate fluid removal alone. There is no survival benefit — and that is not the goal. The goal is getting the patient to a wedding, out of bed, or simply comfortable at home. Home IV inotrope programs exist in many hospice-supporting hospital systems. The ethical framework is well-established: symptom relief is the indication, not hemodynamic targets.

Requires IV access and monitoring plan
Discuss goals explicitly: comfort, not survival
Milrinone preferred in concurrent beta-blocker use

Home IV Diuresis / SQ Furosemide

Grade B

IV furosemide 40–120 mg intermittently · SQ furosemide 20–80 mg/day via butterfly · Prevents hospitalization

Intermittent IV or subcutaneous diuresis in the home setting is underutilized and can prevent the cycle of repeated hospitalizations that diminishes quality of life in advanced CHF.^[41] Furosemide can be administered subcutaneously via butterfly needle — a route that requires no IV access, that families can manage with training, and that provides meaningful diuresis in diuretic-responsive patients. Gheorghiade et al. (2009) documented the safety and feasibility of home IV diuresis programs.^[41] For patients with diuretic resistance, combining subcutaneous furosemide with oral metolazone 30 minutes prior significantly augments response. This approach keeps patients at home — where they want to be.

SQ site: abdomen or thigh with 25G butterfly
Max 80 mg SQ per site; can alternate sites
Monitor weight daily; call with 2 lb gain

Cardiac Rehabilitation in Palliative Setting

Grade B

Protocol: Gentle structured exercise 3×/week · Walking program, seated exercise, resistance bands · Supervised or guided

Exercise-based cardiac rehabilitation improves functional capacity, reduces dyspnea, and enhances quality of life even in NYHA Class III CHF patients.^[3] In the palliative context, the goal is not cardiac conditioning — it is maintaining functional capacity long enough to preserve meaningful activities of daily living and quality time at home. Structured walking programs, even 10–15 minutes daily, preserve muscle mass, reduce the deconditioning that worsens dyspnea, and provide psychological benefit. For NYHA IV patients, very gentle seated exercise or physical therapy-guided movement preserves dignity and reduces caregiver burden. The question is not "can this patient exercise?" but "what movement can this patient still do?"

Acupuncture for CHF Symptoms

Grade C

Protocol: Traditional acupuncture 1–2×/week · Electroacupuncture at defined points · 8–12 session course

Limited but growing evidence suggests acupuncture may reduce dyspnea, fatigue, and anxiety in patients with advanced CHF through autonomic modulation. Small randomized trials have shown improvements in 6-minute walk distance and quality of life scores in stable CHF, though data specific to hospice-level CHF are lacking. In palliative patients, acupuncture is most useful for symptom clusters — dyspnea plus anxiety plus insomnia — where a single intervention may address multiple burdens. Safety is excellent in anticoagulated patients when performed by trained practitioners using superficial needling. Community acupuncturists often offer sliding-scale or home visits for hospice patients.

Music Therapy

Grade B

Protocol: Live or recorded music · 20–30 min sessions · Patient-preferred genres · Certified music therapist optimal

Multiple RCTs and systematic reviews support music therapy for reducing anxiety, improving hemodynamic parameters, and enhancing quality of life in hospitalized CHF patients. In hospice settings, music therapy addresses the existential burden of CHF: the loss of physical identity, the fear of breathlessness, the isolation. A certified music therapist can facilitate life review through music, reduce the anxiety component of dyspnea, and create shared family experiences that endure as memories. Preferred music activates reward circuits that counteract the autonomic arousal driving anxiety-mediated dyspnea. Streaming services or tablet-based playlists are adequate when certified therapists are unavailable.

Patient selects preferred music — never assume genre
Can reduce need for anxiolytic medications in some patients
Include in interdisciplinary care plan

S08Everyone

Natural & Herbal Options

Evidence grading, dosing, drug interaction flags, and contraindications specific to CHF. Patients will use supplements — this section equips you to have the right conversation before harm occurs.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"CHF is the supplement danger zone I worry about most. Electrolytes are on a knife's edge — loop diuretics are stripping potassium and magnesium daily, ACE inhibitors are holding potassium in, and then a patient adds a high-potassium supplement or a diuretic herb and we're suddenly managing a dangerous arrhythmia. Every CHF patient I see, I ask about supplements at every single visit. Not once at intake — every visit. They add things. Their family members bring things. 'My cousin said this helps the heart.' Ask. Know what's in the cabinet."

— Waldo, NP · Terminal2

Herb / Supplement	Evidence Grade	Typical Dose	Potential Benefit	⚠ Interactions / Contraindications
Coenzyme Q10 / Ubiquinol	Grade B	100–200 mg daily with fatty meal	Mitochondrial cofactor depleted in CHF; Q-SYMBIO trial showed reduced major adverse cardiac events and improved NYHA class with CoQ10 300 mg/day vs. placebo in severe CHF^[32]	May potentiate warfarin (monitor INR); generally well tolerated; fat-soluble — take with food; ubiquinol form has superior absorption in older adults
Hawthorn (Crataegus extract)	Grade B	160–900 mg/day standardized extract	Mild positive inotropic and vasodilatory effects; Cochrane review (2008) found modest improvement in exercise tolerance and symptom scores in NYHA II–III CHF^[33]	Potential additive effect with digoxin (monitor levels); may potentiate antihypertensives; avoid in NYHA IV without clinician supervision; onset of benefit 8+ weeks — limited utility in very late-stage CHF
Magnesium Glycinate	Grade C	200–400 mg elemental magnesium daily	Loop diuretics cause significant magnesium wasting; hypomagnesemia increases arrhythmia risk and worsens diuretic resistance; replacement may improve rhythm stability and reduce cramps	Avoid if GFR <30 mL/min (renal accumulation); check serum magnesium first; may cause diarrhea — glycinate form better tolerated; do not use magnesium oxide (poor bioavailability); monitor in renal impairment
Omega-3 Fatty Acids (Fish Oil)	Grade B	1–4 g EPA+DHA daily	GISSI-HF trial: n-3 fatty acids 1 g/day reduced all-cause mortality and cardiovascular admissions modestly in CHF patients over median 3.9 years^[31]; anti-inflammatory; may reduce sudden cardiac death risk	Antiplatelet effect — increased bleeding risk with anticoagulants; at >3 g/day may raise LDL; use purified fish oil with low mercury contamination; generally safe at 1–2 g/day in anticoagulated patients with monitoring
Thiamine (Vitamin B1)	Grade B	100–200 mg daily	Furosemide causes significant urinary thiamine loss; thiamine deficiency causes wet beriberi — a reversible form of high-output heart failure that worsens underlying CHF; replacement may improve cardiac function in deficient patients	Extremely safe; water-soluble; no significant drug interactions; check B1 level if available in patients on long-term furosemide; deficiency underdiagnosed in advanced CHF — screen empirically
Ginger Root	Grade B	250–500 mg/day standardized extract	Evidence-based for nausea (Grade A in pregnancy/chemo); in CHF useful for hepatic congestion-related nausea, anorexia, and abdominal discomfort from bowel wall edema	Antiplatelet effect — avoid high doses (>4 g/day) in patients on anticoagulation; may lower blood glucose (monitor in diabetics); mild BP-lowering effect; drug-food interaction with warfarin at high doses
D-Ribose	Grade C	5 g three times daily	Pentose sugar; substrate for ATP synthesis; small studies suggest improved energy levels and functional capacity in ischemic cardiomyopathy; thought to replenish cardiac ATP depleted in ischemic CHF	May lower blood glucose — use with caution in diabetics on hypoglycemics; generally well tolerated; very limited safety data at doses >60 g/day; evidence base small and industry-supported; use with informed consent about evidence limitations
L-Carnitine	Grade C	1–3 g daily in divided doses	Mitochondrial fatty acid transporter; deficient in some CHF patients; small studies show improved exercise tolerance and ejection fraction in ischemic cardiomyopathy; may improve fatigue and functional capacity	Fishy body odor at high doses; may increase TMAO (trimethylamine N-oxide) — theoretical cardiovascular concern; avoid in renal failure (TMAO accumulates); warfarin interaction possible — monitor INR; limited high-quality evidence

🚫 Avoid in CHF — Clinically Significant Risks

Licorice Root (Glycyrrhiza): Contains glycyrrhizin — causes pseudohyperaldosteronism: sodium retention, potassium wasting, hypertension. Directly worsens CHF fluid status and creates dangerous hypokalemia in patients already on loop diuretics. Even licorice candy in large amounts is a risk. Contraindicated.
St. John's Wort (Hypericum perforatum): Potent CYP3A4 inducer — reduces plasma levels of digoxin, warfarin, many statins, and antiarrhythmic drugs by 25–50%. Can precipitate drug toxicity with dose reduction or loss of efficacy. Absolutely contraindicated in patients on any cardiovascular polypharmacy.
Ephedra / Ma Huang: Sympathomimetic — increases heart rate, blood pressure, and myocardial oxygen demand. Directly arrhythmogenic in a diseased heart. Contraindicated in any structural heart disease. Associated with sudden cardiac death in otherwise healthy individuals.
High-dose Vitamin E (>400 IU/day): HOPE-TOO trial and meta-analyses suggest increased risk of heart failure and hemorrhagic stroke at doses >400 IU/day. Paradoxically harmful in populations expected to benefit. Avoid supplemental vitamin E in CHF; dietary sources are safe.
Ginkgo Biloba: Antiplatelet effect — significant bleeding risk when added to anticoagulation or antiplatelet therapy common in CHF patients. No established cardiac benefit. Risk-benefit ratio unfavorable in this population.
Noni Juice (Morinda citrifolia): Very high potassium content — dangerous hyperkalemia risk in patients on MRAs (spironolactone/eplerenone) and ACE inhibitors/ARBs, all of which are potassium-sparing. Potentially fatal arrhythmia risk. Also rare hepatotoxicity reported.
High-dose Garlic Supplements (>900 mg/day): Significant antiplatelet and mild antihypertensive effects — increases bleeding risk with anticoagulation and may cause symptomatic hypotension in volume-depleted CHF patients. Culinary garlic is safe; concentrated supplements are not.

S09Everyone

Timeline Guide

CHF follows a sawtooth trajectory — not the linear decline of cancer. Each decompensation may look like the last, until suddenly recovery is incomplete. Use this guide to set expectations, not predictions.

CHF is the most prognostically uncertain disease in hospice medicine. Unlike cancer, which typically follows a relatively predictable downward arc, CHF produces a sawtooth pattern: acute decompensations that appear life-threatening, followed by partial recoveries that restore false confidence — until the trajectory finally crosses a threshold from which meaningful recovery is no longer possible.^[26]^[27] The Seattle Heart Failure Model and MAGGIC score can quantify 1- and 5-year mortality risk, but cannot predict the timing of a specific decompensation or death. The clinical skill is reading the direction of the trajectory — even when the patient looks stable today — and using that direction to prepare families, manage devices, and ensure comfort measures are in place before the next crisis, not during it.^[10]

The question to ask at each visit: "Is this patient recovering as completely as they did last time?" When the answer is no — when diuretic doses are climbing, when GDMT is being reduced for hypotension, when NYHA class is drifting toward IV — the trajectory has shifted. Act accordingly.

YRS–
MOS

ACC/AHA Stage C — Symptomatic CHF on GDMT

NYHA Class II–III; functional but symptomatic; on optimized guideline-directed medical therapy (GDMT) — ACE/ARB/ARNI + beta-blocker + MRA + SGLT2i
Hospitalizations for decompensation are occurring but recovery is meaningful — patient returns to near-baseline functional status
EF may be improving with therapy (HFrEF); symptoms may be better controlled with medication titration
ICD and CRT decision point: devices are being considered or already implanted; these conversations must happen while patient has cognitive capacity to participate
Palliative care integration at Stage C improves quality of life and increases advance care planning completion without reducing survival (PAL-HF)^[10]
Focus: advance care planning, ICD conversation, establish goals, ensure GDMT is optimized

MOS–
1 YR

Stage C→D Transition — Decompensations Accumulating

Decompensations becoming more frequent and recovery less complete after each hospitalization — the defining sign of trajectory shift
NYHA class fluctuating III–IV; dyspnea now present at minimal exertion or rest; orthopnea worsening
GDMT being reduced or discontinued due to progressive hypotension, worsening renal function (cardiorenal syndrome), or hyperkalemia
Diuretic doses escalating; diuretic resistance beginning to appear (thiazide augmentation required)
Recurrent pleural effusions, ascites, or progressive anasarca — may require recurrent thoracentesis or paracentesis
ICD conversation urgency escalates: the device will continue to deliver shocks unless a plan is made now
Focus: diuretic optimization, ICD deactivation conversation, goals-of-care deepening, hospice enrollment discussion

WKS–
MOS

Refractory Stage D — Hospice Enrollment Appropriate

NYHA IV at rest; unable to perform minimal activity without dyspnea; often bed-chair bound
Cannot tolerate GDMT due to hemodynamic compromise; ACE inhibitors and beta-blockers reduced or stopped
Diuretics are the primary active tool; metolazone augmentation, SQ furosemide, or intermittent IV diuresis being used
Multiple hospitalizations in preceding 6 months; each hospitalization associated with higher 30-day mortality
Refractory fluid congestion: massive leg edema with weeping, tense ascites, recurrent pleural effusions despite maximal diuresis
ICD deactivation must occur — if not already done, it is now urgent. An active ICD in a dying patient guarantees painful shocks.
Hospice enrollment is indicated and guideline-supported; palliative inotropes may be offered as bridge to comfort^[30]
Focus: comfort kit preparation, ICD deactivation, family education about Cheyne-Stokes, diuretic titration for symptom relief only

DAYS–
WKS

Active Dying — Low Cardiac Output State

Anasarca with refractory fluid accumulation despite maximal diuresis; the kidneys can no longer respond
Cheyne-Stokes respiration emerging or established — periodic breathing with central apneas, crescendo-decrescendo cycles; caused by low cardiac output reducing CO₂ sensitivity and prolonging circulation time to respiratory centers
Confusion, somnolence, and poor concentration from low cerebral perfusion — cardiogenic encephalopathy; may fluctuate
Oral intake markedly reduced or absent; dysphagia may develop
Opioids are the primary comfort tool — morphine addresses both dyspnea and the air-hunger that accompanies Cheyne-Stokes; titrate aggressively
ICD MUST be deactivated if not already — this is a clinical emergency in a dying patient. Use magnet at bedside as immediate bridge.
Family preparation for Cheyne-Stokes is critical: explain the mechanism, explain it is not suffocation, explain what the breathing pattern means. A prepared family watches with calm; an unprepared family calls 911.
Focus: opioid titration, ICD deactivation, family vigil preparation, symptom control around-the-clock

HRS–
DAYS

Final Hours — Terminal Circulatory Failure

Cheyne-Stokes with prolonged central apneas (10–60+ seconds) — families will need moment-to-moment reassurance during apneic episodes
Mottling of knees, ankles, and feet progressing proximally — sign of peripheral circulatory failure
Minimal responsiveness; auditory awareness may persist — family should continue to speak, touch, and be present
ICD magnet at bedside at all times; any ICD shock in this phase is a medical emergency of a different kind — the patient is dying, not recoverable
Comfort medications continuous: morphine CSCI for dyspnea, midazolam for terminal agitation, glycopyrrolate for secretions
Diuretics may be discontinued — they no longer serve comfort and cannot be absorbed; the kidneys have failed
Family vigil support: the hospice team should be present or available by phone continuously; the family needs to know they are not alone

S10Clinician

Medications to Anticipate

CHF pharmacology in hospice: what to keep, what to stop, and what to add for comfort. Deprescribing life-prolonging GDMT in a dying patient is not abandonment — it is comfort care.

The deprescribing principle in Stage D CHF: As CHF progresses toward death, the medications that have prolonged life — ACE inhibitors, ARBs, ARNI, beta-blockers, SGLT2 inhibitors, statins, antiplatelets — lose their survival benefit and accumulate only their side effects: hypotension that prevents adequate diuresis, bradycardia that limits cardiac output, renal toxicity that worsens the cardiorenal syndrome. Stopping GDMT in a dying patient is evidence-based, guideline-supported, and ethically sound.^[3]^[43] The sequence: stop statins and antiplatelets first (no comfort benefit), then ACE/ARB/ARNI if causing hypotension or renal failure, then beta-blockers if causing bradycardia limiting cardiac output, then SGLT2i (limited data but low risk profile). Diuretics remain the last tool standing — they are comfort medications in CHF, not GDMT. Continue until the kidneys cannot respond.

Drug	Class / Target Symptom	Starting Dose	Notes / Cautions
Furosemide	Loop diuretic / Volume overload, dyspnea	40–240 mg PO/IV daily	Cornerstone of CHF symptom management; IV route 2× more bioavailable than PO; SQ route via butterfly needle effective for home diuresis; torsemide preferred for superior and more consistent oral bioavailability; titrate to symptom relief not to weight target in hospice.^[36]
Torsemide	Loop diuretic / Volume overload (preferred)	10–100 mg PO daily	Superior oral bioavailability (80–100% vs 40–60% for furosemide); more predictable response; consider switching if furosemide response is variable; 20 mg torsemide ≈ 40 mg furosemide; use when oral reliability is important at home. Switch furosemide to torsemide 1:2 ratio (furosemide mg ÷ 2 = torsemide mg).
Metolazone	Thiazide-like diuretic / Diuretic resistance	2.5–5 mg PO 30 min before loop diuretic	Sequential nephron blockade — dramatically augments loop diuretic response in resistant patients; give 30 minutes before furosemide/torsemide; monitor electrolytes closely (profound potassium/magnesium loss); use intermittently 2–3×/week initially; powerful tool in refractory Stage D CHF. ⚠ Check electrolytes within 48–72h of initiation.
Spironolactone / Eplerenone	MRA / Adjunct diuresis, neurohormonal blockade	12.5–50 mg PO daily	Continue if potassium and renal function allow; provides additive diuresis and reduces aldosterone-driven fluid retention; stop if K⁺ >5.5 mEq/L or GFR falling rapidly; eplerenone preferred if gynecomastia develops; RALES trial: 30% mortality reduction in severe CHF.^[21]
Morphine	Opioid / Dyspnea (primary comfort drug)	2.5–5 mg PO/SQ q4h + 2.5 mg q1h PRN	Most important comfort medication in advanced CHF; evidence-based first-line for refractory dyspnea; chronically underprescribed due to unfounded fears. Write scheduled dose + robust PRN at enrollment. Titrate by 25–33% every 24–48h for persistent dyspnea. SQ route equally effective when oral route unavailable.^[15]^[18] ⚠ Reduce dose 25–50% if GFR <30; avoid in severe renal failure — use hydromorphone instead.
Lorazepam	Benzodiazepine / Anxiety component of dyspnea	0.5–1 mg PO/SQ q4–6h PRN	Anxiety amplifies the perception of breathlessness in CHF; lorazepam addresses this component; do not use as sole dyspnea agent (opioids are primary); additive with morphine for severe dyspnea; avoid scheduled use in ambulatory patients due to fall risk; SQ route effective in non-oral patients.
Midazolam	Benzodiazepine / Refractory dyspnea, terminal agitation	2.5–5 mg SQ PRN · CSCI 10–20 mg/24h	Gold standard for terminal agitation and refractory dyspnea unresponsive to opioid titration; water-soluble — compatible with morphine in CSCI; short half-life allows rapid titration; must be pre-drawn and labeled in comfort kit; opioid-sparing effect at higher doses. ⚠ Have pre-drawn, labeled syringe at bedside before final days — do not wait for crisis to prepare.
Haloperidol	Antipsychotic / Nausea, delirium, agitation	0.5–2 mg PO/SQ q6–8h	Nausea in CHF is common: hepatic congestion impairs drug metabolism, bowel wall edema causes early satiety and nausea, low cardiac output causes mesenteric ischemia; haloperidol is the hospice-preferred antiemetic and antidelirium agent; SQ route well tolerated; QTc prolongation possible — avoid if known long QT or hypokalemia.
Glycopyrrolate	Anticholinergic / Terminal secretions	0.2 mg SQ q4h · 0.6–1.2 mg/24h CSCI	Reduces terminal secretion production without CNS penetration (preferred over hyoscine/scopolamine in patients who may remain conscious); in CHF, pulmonary edema can be confused with secretions — glycopyrrolate is specific to secretions; have in comfort kit pre-drawn; does not treat Cheyne-Stokes (opioids do).
Dexamethasone	Corticosteroid / Nausea, appetite stimulation, refractory dyspnea	2–4 mg PO/SQ daily (morning dose)	Short-term use (2–4 weeks) for refractory nausea, appetite stimulation, or dyspnea with significant inflammatory component; in CHF, use with caution — sodium retention effect can worsen fluid overload; weigh symptom benefit against edema risk; useful for acute symptom crises, not chronic use; stop if fluid status worsens significantly.
Ondansetron	5-HT₃ antagonist / Nausea adjunct	4–8 mg PO/SQ/ODT q8h PRN	Adjunct antiemetic for hepatic congestion nausea, opiate-induced nausea, or multi-factorial nausea in CHF; ODT formulation useful when swallowing is difficult; no significant cardiac caution at standard doses; consider QTc monitoring if combined with haloperidol; well tolerated in renal impairment.
Nitroglycerin SL	Nitrate / Acute pulmonary edema, dyspnea crisis	0.4 mg SL q5 min × 3 PRN acute dyspnea	For acute severe dyspnea from pulmonary congestion — venodilation rapidly reduces preload and relieves acute flash pulmonary edema; effective even in the home setting; teach family when and how to use; avoid if systolic BP <90 mmHg; do not use with PDE-5 inhibitors (sildenafil, tadalafil) — severe hypotension. ⚠ Check BP before each dose if monitored.
Dobutamine / Milrinone	Inotrope / Refractory Stage D symptom palliation	Dobutamine 2.5–10 mcg/kg/min IV · Milrinone 0.1–0.375 mcg/kg/min IV	Palliative inotrope infusion for refractory Stage D CHF when comfort — not survival — is the goal; ACC/AHA Class IIb indication; can dramatically reduce dyspnea and fatigue; no survival benefit; may be offered via home infusion with hospice coordination; milrinone preferred if on beta-blocker (dobutamine efficacy reduced); arrhythmia risk.^[42]^[45]

🌿 Symptom Management Decision Tree

Evidence-based · Hospice-adapted · CHF

Select a symptom below to begin

What is the primary symptom to address?

🚨 CHF Comfort Kit Must-Haves — Have These Before the Crisis

Morphine 5 mg/mL SQ: For dyspnea crisis — pre-drawn, labeled, refrigerated. Family and on-call nurse must know exactly where it is and how to give it. This is the most important drug in the kit.
Midazolam 5 mg/mL SQ: For refractory dyspnea or terminal agitation unresponsive to morphine. Pre-drawn, labeled. The backup to morphine, not a substitute.
Glycopyrrolate 0.2 mg SQ: For terminal secretions — have it drawn and labeled. Can be given by family with instruction.
Lorazepam 0.5–1 mg SQ/SL: For anxiety component of dyspnea crisis or agitation. SL formulation useful when SQ access is unavailable.
Nitroglycerin 0.4 mg SL tablets: For acute pulmonary congestion dyspnea — ensure supply is not expired; teach family the 3-dose protocol.
ICD Magnet (device-specific or universal donut magnet): Know the patient's ICD manufacturer. Have the magnet at bedside before the final days. If ICD has not been formally deactivated, the magnet is a temporary suspension of shock therapy — tape over device, document location. Permanent deactivation is the definitive solution.
Furosemide 10 mg/mL for SQ use: Subcutaneous butterfly needle and supplies; furosemide for SQ diuresis if oral route is unavailable in final days.

S11Clinician

Clinician Pointers

High-yield CHF-specific clinical pearls for the hospice team. The things you learn after doing enough of these cases. Not guidelines — real.

ICD Conversation Is Your Clinical Obligation — Ask at the First Visit

Do not wait for the cardiologist to have this conversation. Ask at enrollment: "Does your patient have an ICD? Has anyone talked to you about what happens to it when the time comes?" The HRS Expert Consensus Statement (Lampert 2010) explicitly states that ICD deactivation is ethically permissible and legally sound at patient request — and that hospice clinicians bear responsibility for initiating this discussion.^[12] Without deactivation, a dying patient with an active ICD will receive repeated defibrillatory shocks in their final hours. This is a preventable harm that happens when clinicians defer this conversation. Do not defer it.

Daily Weight Is the Only Early Warning System You Have

In CHF, the scale is your stethoscope. A weight gain of 2 lbs in one day or 5 lbs over one week consistently predicts an impending decompensation and hospitalization — often 24–72 hours before dyspnea becomes symptomatic.^[3] Teach every family member how to weigh correctly: same scale, first thing in the morning, after urination, before eating. Write the baseline weight in the chart. Have a clear action plan tied to the threshold: "Call me when weight is up 2 pounds." Without daily weighing, you are responding to crises rather than preventing them. In the hospice context, a weight gain threshold may trigger diuretic adjustment rather than hospitalization — but you cannot act on information you don't have.

Opioids for Dyspnea in CHF Are Evidence-Based and Chronically Underprescribed

Morphine for dyspnea in CHF is supported by systematic review, endorsed by the AHA/ACC, and recommended in every major hospice palliative care guideline.^[15]^[18] It is also, consistently, one of the most underprescribed medications in this population. The fear of respiratory depression at comfort doses is not evidence-based. Morphine reduces the sensation of breathlessness without clinically significant oxygen desaturation at starting doses of 2.5–5 mg. Write the order at enrollment. Write scheduled doses plus robust PRNs. Reteach the patient and family at every visit that this medication is for breathing, that it is safe, and that using it as prescribed is the right thing to do. Many CHF patients suffer needlessly because their families are afraid to give the morphine the hospice nurse ordered.

Prepare Families for Cheyne-Stokes Breathing Before It Happens

Cheyne-Stokes respiration is terrifying if you don't know it's coming. It sounds like the patient is stopping breathing repeatedly — because they are. The mechanism is reduced cardiac output increasing circulation time and blunting CO₂ sensitivity at the respiratory center, causing the crescendo-decrescendo-apnea cycle. When families see this for the first time without preparation, many call 911. An unprepared family calls for resuscitation. A prepared family watches with calm, knowing this is expected, knowing their person is not suffering, knowing you told them exactly this would happen. Every CHF patient in the final weeks: "I want to tell you what the breathing may look like as things progress. There's a breathing pattern that often happens with heart failure — it goes in and out, there may be pauses. This is called Cheyne-Stokes breathing. When you see it, call us. But know that it is expected and your loved one is not suffocating."

Deprescribing Is a Comfort Skill — Know the Sequence

As CHF progresses, GDMT transitions from life-prolonging to burden-adding. Know which medications to stop first and why.^[43] Stop statins and antiplatelets early — no comfort benefit, pill burden only. Stop ACE/ARB/ARNI when causing symptomatic hypotension or worsening cardiorenal syndrome — they cannot help when the kidneys cannot respond. Stop beta-blockers when causing symptomatic bradycardia or limiting cardiac output — they may be allowing compensatory tachycardia that is the only thing maintaining perfusion. Reduce SGLT2 inhibitors — limited evidence for continuation in hospice; monitor for DKA risk in diabetics. Keep diuretics last — these are comfort medications. Keep opioids, antiemetics, anxiolytics. The patient who is dying on 14 medications deserves the same careful medical management as any other patient — including the management of getting off the medications that are no longer helping.

Know the ICD Magnet Protocol Before You Need It

Different ICD manufacturers respond differently to magnet application. For most devices, placing a ring magnet directly over the ICD generator will suspend tachyarrhythmia detection and prevent shock delivery for as long as the magnet is in place — a temporary measure while permanent deactivation is arranged.^[12]^[13] Boston Scientific devices: magnet suspends therapy permanently (must be removed to resume). Medtronic devices: magnet suspends therapy while in place; removes automatically when magnet is removed. Abbott/St. Jude Medical: same as Medtronic. Know your patient's device type from their wallet card or device clinic records. Carry a donut magnet in your clinical bag. In a dying patient receiving ICD shocks: tape the magnet over the device, call the hospice medical director, arrange for formal deactivation the same day. Document everything.

Diuretic Resistance Is Common — Know Your Tools

In advanced CHF, oral furosemide bioavailability falls from 50–60% to as low as 10–20% due to bowel wall edema impairing absorption — so the dose that worked for years stops working.^[36] Tools for diuretic resistance: (1) Switch to torsemide — superior and more consistent oral bioavailability; (2) Add metolazone 2.5–5 mg PO 30 minutes before the loop diuretic — sequential nephron blockade dramatically augments response but causes profound electrolyte loss; (3) Switch to IV or SQ furosemide — bypasses gut absorption problem; (4) Continuous IV furosemide infusion for refractory inpatient decompensation. In hospice, the goal of diuresis is symptom relief — dyspnea, edema, abdominal fullness — not a target weight or BNP. Titrate to comfort, not to numbers.

Racial Disparities in CHF — The Clinician's Role at the Bedside

Black Americans have a 2–3× higher rate of CHF hospitalizations than white Americans, develop CHF at younger ages (mean 10 years earlier), have worse outcomes, and are significantly less likely to be referred for advanced therapies including LVAD and cardiac transplant evaluation.^[47]^[48] Isosorbide dinitrate/hydralazine (BiDil) is FDA-approved specifically for Black patients with HFrEF who cannot tolerate ACE inhibitors and provides a mortality benefit in that population.^[3] In hospice, the disparity continues: Black patients with CHF are less likely to receive opioids for dyspnea, less likely to have advance directives, and more likely to die in hospital. The hospice clinician's role is not passive: document race, explicitly assess for barriers to equitable care, ensure opioids are prescribed, ensure advance directives are offered, and be a consistent advocate for every patient at your bedside regardless of who they are.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The CHF patient who worries me most is the one who looks better than they are. They sit up, they greet me, their vitals look almost okay, they make a joke — and their labs tell a completely different story. BNP is 3,000. Creatinine is climbing. They've been to the ER twice in six weeks. This is what cardiac compensation looks like — it masks severity until it suddenly, catastrophically doesn't. I've seen these patients go from sitting in the recliner to unresponsive in 18 hours. Prepare the family before it happens. You cannot prepare a family during it."

— Waldo, NP · Terminal2

S12EveryoneClinician

Psychosocial & Spiritual Care

CHF-specific existential distress: ICD grief, prognostic uncertainty, identity loss, caregiver burden, and the depression that worsens outcomes in 20–40% of patients. The symptom burden you cannot see on a vitals sheet.

CHF creates a distinct constellation of psychosocial suffering that differs fundamentally from cancer. The sawtooth trajectory — repeated decompensations and partial recoveries — generates chronic prognostic uncertainty that prevents patients from mentally preparing for death even when they know it is coming. The devices they carry have been their lifelines; deactivating them feels like choosing to die. Their identities — especially for men — have been built around physical capacity now erased by NYHA IV limitations. Depression affects 20–40% of CHF patients and independently worsens cardiac outcomes, yet it is systematically underdiagnosed and undertreated in this population.^[44]

Your job is not to provide answers. Your job is to create the space where the right questions can be asked — and to connect patients and families with the right people before a crisis forces the conversation.

Psychological Distress Screening

Depression in CHF — Screen Every Patient

Grade B

Depression prevalence in advanced CHF is 20–40%, two to three times the general population rate, and is an independent predictor of rehospitalization and mortality.^[44] It is systematically underdiagnosed because clinicians attribute low energy, poor appetite, and withdrawal to the cardiac disease itself — missing a treatable co-morbidity.

Single-question screen: "Are you depressed?" has high sensitivity in terminally ill patients when asked directly and with genuine intent
PHQ-2: "Over the last 2 weeks, have you felt down, hopeless, or little pleasure in doing things?" Score ≥3 warrants full PHQ-9
Mirtazapine 7.5–15 mg QHS: First-line in hospice CHF — simultaneously addresses depression, insomnia, and anorexia; faster onset than SSRIs; minimal cardiac effects at low doses
Distinguish grief from clinical depression — both deserve attention; only depression warrants pharmacotherapy
Screen at enrollment, at major transitions, and after hospitalizations

Anxiety & the Dyspnea-Anxiety Cycle

Grade B

Anxiety and dyspnea are mutually amplifying in CHF: breathlessness triggers anxiety, which increases sympathetic tone and myocardial oxygen demand, which worsens cardiac output, which increases breathlessness. Breaking this cycle is a clinical priority.

Non-pharmacological first: Fan on face, repositioning, open window, calm presence — address the physiological trigger
Lorazepam 0.5 mg PRN for acute anxiety episodes — avoid scheduled use in ambulatory patients; significant fall risk
Buspirone 5 mg BID for chronic anxiety: no CNS depression, no dependence — useful in ambulatory patients with generalized anxiety
Refer to social work and chaplain at enrollment — not at crisis. Waiting until a crisis is a clinical failure.
Assess for hospital-related PTSD: repeated ICU admissions, cardioversion experiences, and code events create trauma that shapes end-of-life anxiety

CHF-Specific Psychosocial Challenges

ICD Grief — The Device as Symbol of Hope

For many patients, the ICD is not just a device — it is the reason they are alive. Being asked to deactivate it is experienced as being asked to choose death. This is a profound psychological transition that requires skilled, compassionate facilitation — not just an informed consent conversation.

Acknowledge what the device has meant: "This device has protected you. That's real."
Frame deactivation as removing a burden, not choosing death: "Your heart failure is what is life-limiting. The ICD cannot change that now."
Involve chaplaincy — this is fundamentally a spiritual and existential conversation as much as a clinical one
Allow grief about the decision — it does not need to be resolved quickly
Some patients will refuse deactivation — document, respect, revisit. It is their right.^[12]

Cardiac Identity & Masculinity — Functional Grief

CHF disproportionately affects older men who have built their identity around physical capacity — working, providing, being strong. NYHA IV functional loss strips away the activities that defined them: yard work, driving, intimacy, independence. This is a specific form of anticipatory grief that deserves clinical recognition, not just sympathy.

Assess functional losses explicitly: "What were you able to do six months ago that you can't do now?"
Name the grief: "Losing those abilities is a real loss. It's okay to grieve them."
Explore legacy and meaning: "What do you want your family to remember about who you've been?"
Refer to social work for life review interventions — dignity therapy is evidence-based for reducing existential distress
Involve family members in legacy work — photographs, recordings, letters

Prognostic Uncertainty — The Sawtooth Problem

CHF prognosis is notoriously uncertain. Patients repeatedly recover from decompensations that looked terminal — then find that their next hospitalization is their last. This uncertainty prevents meaningful end-of-life preparation and creates perpetual cognitive dissonance between knowing death is coming and experiencing recovery.

Use direct language: "The direction of your illness is clear, even though the timing is not."
Anchor hope in concrete realities: "We can't predict the timing, but we can manage what's coming."
Normalize the trajectory: "What you're experiencing — getting better, then worse — is how heart failure works."
Use the trajectory framing: "Is recovery as complete as it was last time? That's the question that matters."

Caregiver Education Burden in CHF

CHF caregiving is objectively more complex than cancer caregiving. Daily weights, fluid restriction logs, medication management, ICD emergency protocols, recognizing decompensation — caregivers carry an enormous cognitive and emotional load that is specific to this disease.^[46]

Assess caregiver burden explicitly at every visit — not just patient symptoms
Simplify the monitoring regimen as disease progresses: in Stage D, daily weight is a trigger for comfort measures, not hospitalization
Ensure caregivers know the ICD magnet protocol before the final days
Refer to caregiver support resources; ensure respite care is offered
Name caregiver exhaustion directly: "You are managing an enormous amount. That is hard. How are you doing?"

Spiritual Assessment

Spirituality in CHF carries a dimension specific to the disease: many patients feel they "cheated death" multiple times — through defibrillation, through hospitalizations, through recovery. There is often a question about meaning: "Why am I still here?" and, as decline progresses, "Why is this taking so long?" Use the FICA framework: Faith/beliefs, Importance, Community, Address. Ask: "What gives you strength during this time?" This opens spiritual conversation without assuming any tradition. Chaplain involvement should be routine at enrollment — not reserved for crisis.^[44]

Clinical Pearl

In CHF patients who have survived sudden cardiac arrest from an ICD shock, there is often profound existential reckoning: "I was dead and then I wasn't." This experience can be deeply isolating — they may feel they cannot talk about it with family for fear of frightening them. Ask directly: "Have you ever had the ICD fire? What was that like for you?" Creating space for this narrative is a clinical intervention, not optional conversation.

01
Ask about faith community explicitly at enrollment: "Is there a faith community or spiritual leader who should know you're ill and might want to visit?" Most patients will not volunteer this without being asked. Many find faith becomes the primary source of strength as medical options narrow.
02
Involve chaplaincy at enrollment — not at crisis: Spiritual care is a clinical discipline. Chaplains are the experts at existential distress, legacy work, and ICD grief facilitation. Their job is to walk through the door you open. Open it at the first visit.
03
Legacy and meaning work: "What do you most want your family to remember about you?" is both assessment and intervention. It shifts the conversation from dying to living. In CHF, where so much has been taken — capacity, independence, the ICD — legacy becomes particularly important to preserve.
04
Unfinished business and relationship ruptures: These are clinical problems with real symptom burden. CHF patients who carry unresolved relationship conflict have worse distress at end of life. Don't leave them to chance — ask: "Is there anyone you've been meaning to connect with or say something to?"

Goals-of-Care Communication

Opening the Goals Conversation in CHF

"What is your understanding of where things stand with your heart?" — assesses illness understanding before prognostic disclosure; reveals how cardiologists have framed prognosis
"If your heart gets worse — which it likely will — what matters most to you?" — elicits values without triggering defensive "I'm going to beat this" responses
"What were you hoping for when you started hospice?" — surfaces the goals that motivated enrollment; holds the team accountable to them
"What are you most afraid of?" — identifies the specific fears driving distress: suffocation, pain, shocks, dying alone; these are clinical targets
"We can't predict timing, but we can plan. What do you want to be in place before things change?"

Communication Pitfalls Specific to CHF

Don't conflate ICD deactivation with giving up: These are different decisions. A patient can keep comfort goals while keeping the ICD — though this needs careful discussion about likely outcomes
Don't say "there's nothing more we can do": Diuretics, opioids, comfort positioning, fan therapy, family presence — there is always more to do
Don't minimize Cheyne-Stokes to families: Say it plainly and prepare them specifically; minimizing creates worse panic when it happens
Don't have the ICD conversation once and consider it done: Revisit at each major transition — the patient's goals may change as they experience more shocks or more decline
Sit down. Make eye contact. Leave silence. These conversations require your full presence, not a quick update between tasks.

Suicidal Ideation & Hastened Death Requests

Passive wish for death ("I'm ready for this to be over") is common in advanced CHF and often represents existentially appropriate readiness — it is not the same as active suicidal ideation. The chronic nature of CHF creates a form of "existential exhaustion" that can be clinically indistinguishable from depression without careful assessment. Active suicidal ideation with plan requires immediate psychiatric engagement. In CHF specifically, note that a patient choosing ICD deactivation is not equivalent to suicidal ideation — this distinction must be explicit in documentation and communication.^[12] Do not conflate these. Do not avoid asking. Ask directly: "Sometimes people with this illness tell me they wish things would end sooner. Have you had thoughts like that?"

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"I've never had a patient refuse to talk about the ICD when I asked the right way. The approach that never works: 'We need to discuss deactivating your defibrillator.' The approach that always works: 'That device has saved your life — that's real, and I want to honor that. I also want to make sure we have a plan so that it's working for you, not against you, when the time comes. Can we talk about that?' Nobody refuses that conversation. They've been waiting for someone to have it with them."

— Waldo, NP · Terminal2

S13FamilyEveryone

Family Guide

Plain language for families of CHF patients. Share, print, or read aloud at the bedside. In English and available in Spanish.

Heart failure means the heart is no longer able to pump enough blood to keep the body comfortable. You may be watching your loved one struggle to breathe, swell with fluid, tire from the slightest effort. These things are real, and they are hard to watch. We want you to know: there is a lot we can do to help with these symptoms, and your presence — more than any medicine — is what matters most right now. This guide tells you what to watch for, what you can do, and when to call us.

La insuficiencia cardíaca significa que el corazón ya no puede bombear suficiente sangre para que el cuerpo esté cómodo. Es posible que esté viendo a su ser querido luchar para respirar, hincharse con líquidos o cansarse con el mínimo esfuerzo. Estas cosas son reales y son difíciles de observar. Queremos que sepa: hay mucho que podemos hacer para ayudar con estos síntomas, y su presencia — más que cualquier medicina — es lo que más importa ahora mismo.

What You May See

Shortness of breath: Especially with walking, going to the bathroom, or lying flat. Your loved one may need to sleep propped up on pillows or in a recliner. This is the heart not pumping well, not a lung disease.
Ankle and leg swelling: Fluid builds up because the heart cannot pump it through. Their shoes may not fit. Their belly may feel tight. You may notice sudden weight gain — this is fluid, not food.
Extreme fatigue: They may sleep most of the day. A short conversation may exhaust them. This is expected — the heart is working very hard and cannot keep up.
Cheyne-Stokes breathing during sleep: A breathing pattern that speeds up, slows down, and then pauses — sometimes 10, 20, or 30 seconds. When you see this, do not panic. It is expected. Call us to let us know you're seeing it — but do not call 911.
Confusion or unusual sleepiness: Low blood flow to the brain can cause this. It may come and go. Speak calmly and gently. Familiar voices and faces are comforting even when they cannot respond clearly.
ICD firing (if they have one): A sudden jolt or "punch" to the chest — your loved one may cry out. Note the time. Call us immediately — not 911. We need to know this happened and may need to make changes to the device settings.

How You Can Help

Weigh every morning: Same scale, same time (right after waking and using the bathroom), before eating. Write it in a notebook or on the paper we gave you. Call us if it goes up 2 pounds in one day or 5 pounds over a week — we may need to adjust medications.
Position for easier breathing: Head of bed elevated 30–45 degrees, or a recliner chair. A fan directed at the nose and mouth — not the ceiling — actually helps the sensation of breathlessness. Try it.
Give the breathing medication early: Do not wait until they are gasping. The morphine or other breathing medication is prescribed to prevent severe breathlessness, not just to treat it. Give it as soon as breathing becomes uncomfortable.
Small food offerings, no pressure: Appetite decreases as the heart fails — this is normal and expected. Small, appealing offerings are enough. Do not push food or worry about nutrition at this stage. Presence and comfort matter more than eating.
Keep the environment calm: Reduce visitors and noise during times of rest. Cool, well-ventilated rooms are more comfortable than warm ones. A calm presence is genuinely therapeutic.
Take care of yourself: Caring for someone with heart failure is demanding. You cannot give from an empty cup. Call us when you need support — not just when the patient does. Respite care is available.

📞 Call the Nurse Immediately If You See:

New or worsening shortness of breath that is not helped by the breathing medication within 30 minutes — call right away, do not wait. The ICD fires (a sudden jolt or shock to the chest) — note the time and call us immediately, not 911. Sudden confusion or inability to speak or respond — call us. Weight gain of 2 or more pounds overnight — call in the morning, do not wait for the next scheduled visit. Chest pain or pressure that is new or severe — call us. An inability to lie down flat at all — call us. Swelling so severe that skin is weeping or breaking down — call us. If you are unsure whether to call: call. We would rather hear from you than have you wonder.

🙏 Research consistently shows that heart failure patients who have family members present — who feel connected, who are not alone — have better symptom control and more comfort at end of life. Your presence is not passive. It is therapeutic. Being here, speaking to them, touching their hand — these things matter medically, not just emotionally. You are part of the care team. The most important part.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom from 12+ years at the bedside with CHF patients. The things you learn after doing enough of these cases. Not guidelines — real.

01

The ICD conversation is your obligation, not the cardiologist's — and it belongs at the first visit. I don't care who implanted the device. The patient is on your caseload now, they are dying, and if that ICD has not been addressed, it will deliver multiple painful shocks in their final hours. That is a preventable harm. You prevent it. Ask at enrollment: "Does your loved one have a defibrillator? Has anyone talked with you about what it will do as things progress?" The answer to the second question is almost always no. That conversation is yours now. Have it.^[12]
02

Know the magnet protocol before you need it — carry a donut magnet in your bag. Every ICD manufacturer responds differently to magnet application. Medtronic and Abbott: magnet held over device suspends shock therapy while in place. Boston Scientific: magnet application permanently disables therapy until reprogrammed. Know your patient's device from their wallet card before the final days. If an actively dying patient's ICD fires, that magnet goes on immediately, you tape it in place, you call the medical director, and you arrange permanent deactivation the same day. Do not leave that bedside without a plan. A magnet is not a solution — it is a bridge. Permanent deactivation is the solution.^[12]^[13]
03

Daily weight is the only early warning system you have in CHF, and most families are not doing it correctly. Same scale — not the bathroom scale last year and the doctor's scale today. Same time — first thing in the morning, after urinating, before eating. Write it down. Two pounds gained overnight or five pounds over the week is a decompensation signal 24–72 hours before dyspnea becomes obvious. In hospice, that signal triggers a comfort intervention, not a hospitalization — but you cannot make that call if you don't have the number. The scale goes next to the bed. Not in the bathroom down the hall. Next to the bed.^[3]
04

Morphine for CHF dyspnea is the right drug, it is evidence-based, and it is chronically underprescribed in this population. Write the order at enrollment — not when they call you gasping at 2 AM. Scheduled morphine 2.5–5 mg every 4 hours plus robust PRNs. The family will be afraid to give it. Teach them at every visit that this medication is for breathing, that it is safe at these doses, that not giving it when needed causes suffering. Some families will still hesitate. Some patients will still refuse to take it. That is their right — but it should not be because the nurse never wrote the order or never explained why it matters.^[15]^[18]
05

Prepare families for Cheyne-Stokes breathing before it happens — this is not optional. CHF patients almost universally develop Cheyne-Stokes respiration in the final days: the breathing that speeds up, slows down, and then stops for 10, 20, 30 seconds at a time. Without preparation, the family calls 911 during the first apneic episode. With preparation, they sit beside the bed and hold a hand. Tell them plainly: "I want to describe what the breathing may look like as the heart gets weaker. There will be pauses. The pauses can be long. Your loved one is not suffocating — the brain is adjusting to lower blood flow. When you see this pattern, call me. Do not call 911. I need to know you're seeing it, and I'll be right there with you." Say it. They'll remember it.
06

Deprescribing is a comfort skill, not a failure — and you need to know the sequence. As CHF progresses toward death, medications that prolonged life begin only adding side effects: the ACE inhibitor is now crashing the blood pressure you need to maintain diuresis; the beta-blocker is causing bradycardia when compensatory tachycardia is the only thing keeping perfusion; the statin is a daily pill burden with zero end-of-life benefit. Sequence: statins and antiplatelets go first. Then ACE/ARB/ARNI if hypotension is limiting diuresis. Then beta-blockers if bradycardia is limiting cardiac output. Diuretics stay. Opioids stay. Antiemetics stay. The goal is not fewer medications — the goal is medications that are doing something useful right now for this person today.^[43]
07

Diuretics are your primary tool in CHF hospice — know them, love them, master every route. Oral furosemide bioavailability crashes in fluid-overloaded patients because gut wall edema blocks absorption. Torsemide does not have this problem — its bioavailability is consistent at 80–100%. When furosemide stops working, switch to torsemide before adding anything else. When that stops working, add metolazone 2.5–5 mg thirty minutes before the loop diuretic — but watch the electrolytes within 48 hours, because metolazone plus a loop diuretic can strip potassium and magnesium to dangerous levels. When oral doesn't work at all, go subcutaneous: furosemide 20–80 mg per day via butterfly needle in the abdomen. It works. It keeps patients at home. Most families can learn to give it.^[36]
08

Black Americans bear a disproportionate burden of CHF — and the disparities follow them into hospice. CHF onset is 10 years earlier. Hospitalization rates are two to three times higher. Referral for advanced therapies — LVADs, transplant evaluation — is significantly lower for Black patients with equivalent severity.^[47]^[48] In hospice, opioid prescribing for dyspnea is lower for Black patients. Advance directive completion rates are lower. Death in hospital is more common. The hospice clinician cannot fix the system — but you can be fiercely equitable at your own bedside. Write the morphine order. Ask about advance directives. Don't assume anything. Be present. Every patient in front of you deserves exactly what you would give your own family member. That standard does not vary with race or zip code.
09

Caregiver burden in CHF is objectively more complex than in most other hospice diagnoses — and it is often invisible until it breaks. Daily weights, fluid restriction logs, diuretic timing, medication management across 8–14 drugs, ICD emergency awareness, recognizing decompensation, managing Cheyne-Stokes without panicking — the cognitive load is extraordinary.^[46] Assess the caregiver at every visit, not just the patient. Ask: "How are you sleeping? When did you last leave the house? Who else is helping you?" Offer respite care proactively — don't wait for the caregiver to ask, because many won't. When the caregiver breaks, care for the patient breaks. The caregiver is your co-patient in CHF. Treat them accordingly.
10

The CHF patient who looks stable today may be at the edge of a cliff you cannot see. This is the hardest thing about this disease — compensation masks severity until suddenly, catastrophically, it doesn't. I've had patients greet me with a smile, make a joke, and have their families call me that evening because they stopped breathing. The cardiac reserve is exhausted; what you see clinically is the patient performing compensation, not actual stability. Watch the trend, not the snapshot: Is recovery less complete than last time? Are diuretic doses climbing? Is GDMT being reduced? Is the BNP trending up? These are the real numbers. When the trend says "this direction," believe the trend — and prepare the family now, not after the crisis. You can't take back the conversation you never had.

— Waldo, NP

REFClinician

References

Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–e239.

PMID 23747642 DOIGuideline

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. Circulation. 2017;136(6):e137–e161.

PMID 28455343 DOIGuideline

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895–e1032.

PMID 35363499 DOIGuideline

McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). N Engl J Med. 2014;371(11):993–1004.

PMID 25176015 DOIRCT

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995–2008.

PMID 31535829 DOIRCT

Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). N Engl J Med. 2020;383(15):1413–1424.

PMID 32865377 DOIRCT

Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction (EMPEROR-Preserved). N Engl J Med. 2021;385(16):1451–1461.

PMID 34449189 DOIRCT

Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER). N Engl J Med. 2022;387(12):1089–1098.

PMID 36027570 DOIRCT

Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-ACT). N Engl J Med. 2018;379(11):1007–1016.

PMID 30145929 DOIRCT

Rogers JG, Patel CB, Mentz RJ, et al. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol. 2017;70(3):331–341.

PMID 28359072 DOIRCT

O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF trial. J Am Coll Cardiol. 2010;56(9):692–699.

PMID 20723799 DOIRCT

Lampert R, Hayes DL, Annas GJ, et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm. 2010;7(7):1008–1026.

PMID 20609343 DOIGuideline

Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end-of-life care. Ann Intern Med. 2004;141(11):835–838.

PMID 15583225 DOIReview

Padeletti L, Arnar DO, Boncinelli L, et al. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace. 2010;12(10):1480–1489.

PMID 20858697 DOIGuideline

Blinderman CD, Homel P, Billings JA, Tennstedt S, Portenoy RK. Symptom distress and quality of life in patients with advanced congestive heart failure. J Pain Symptom Manage. 2008;35(6):594–603.

PMID 18495418 DOIObservational

Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet. 2010;376(9743):784–793.

PMID 20816546 DOIRCT

Galbraith S, Fagan P, Perkins P, Lynch A, Booth S. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage. 2010;39(5):831–838.

PMID 20417080 DOIRCT

Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure — a pilot study. Eur J Heart Fail. 2002;4(6):753–756.

PMID 12453546 DOISystematic Review

MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007.

PMID 10023943 DOIRCT

Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med. 2001;344(22):1651–1658.

PMID 11386263 DOIRCT

Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). N Engl J Med. 1999;341(10):709–717.

PMID 10471456 DOIRCT

Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms (EMPHASIS-HF). N Engl J Med. 2011;364(1):11–21.

PMID 21073363 DOIRCT

Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure (REMATCH). N Engl J Med. 2001;345(20):1435–1443.

PMID 11794191 DOIRCT

Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device (HeartMate II). N Engl J Med. 2009;361(23):2241–2251.

PMID 19920051 DOIRCT

Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the ESC practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715–731.

PMID 30989768 DOIGuideline

Pocock SJ, Ariti CA, McMurray JJV, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies (MAGGIC). Eur Heart J. 2013;34(19):1404–1413.

PMID 23095984 DOIMeta-analysis

Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113(11):1424–1433.

PMID 16534009 DOIObservational

Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349(9058):1050–1053.

PMID 9107242 DOIObservational

Rutten FH, Moons KG, Cramer MJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ. 2005;331(7529):1379.

PMID 16321994 DOIObservational

Fang JC, Ewald GA, Allen LA, et al. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J Card Fail. 2015;21(6):519–534.

PMID 25953697 DOIGuideline

GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial). Lancet. 2008;372(9645):1223–1230.

PMID 18757090 DOIRCT

Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC Heart Fail. 2014;2(6):641–649.

PMID 25282031 DOIRCT

Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure (Cochrane review). Cochrane Database Syst Rev. 2008;(1):CD005312.

PMID 18254076 DOISystematic Review

Costanzo MR, Negoianu D, Jaski BE, et al. Aquapheresis versus intravenous diuretics and hospitalizations for heart failure (CARRESS-HF). N Engl J Med. 2012;367(24):2296–2304.

PMID 23131078 DOIRCT

Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome (UNLOAD). N Engl J Med. 2012;367(24):2296–2304.

PMID 17141741 DOIRCT

Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure (Cochrane review). Cochrane Database Syst Rev. 2012;2:CD003838.

PMID 22336795 DOISystematic Review

Ruwald MH, Okumura K, Kimura T, et al. Influence of shocks on mortality and rhythm in patients with ischemic or nonischemic cardiomyopathy and defibrillators. Eur Heart J. 2014;35(23):1659–1667.

PMID 24618145 DOIObservational

Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events (MADIT-CRT). N Engl J Med. 2009;361(14):1329–1338.

PMID 19723701 DOIRCT

Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure (CARE-HF). N Engl J Med. 2005;352(15):1539–1549.

PMID 15753115 DOIRCT

Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics — 2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93–e621.

PMID 36695182 DOIReview

Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the Heart Failure Association of the ESC. Eur J Heart Fail. 2010;12(5):423–433.

PMID 20354029 DOIReview

Hauptman PJ, Mikolajczak P, George A, et al. Chronic inotropic therapy in end-stage heart failure. Am Heart J. 2006;152(6):1096.e1–1096.e8.

PMID 17161066 DOIReview

Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;125(15):1928–1952.

PMID 22392529 DOIGuideline

Adler ED, Goldfinger JZ, Kalman J, Park ME, Meier DE. Palliative care in the treatment of advanced heart failure. Circulation. 2009;120(25):2597–2606.

PMID 20026792 DOIReview

Teerlink JR, Massie BM. The role of inotropes in the management of chronic heart failure. Heart Fail Monit. 2003;4(2):51–57.

PMID 14567360Review

Dunlay SM, Redfield MM, Weston SA, et al. Hospitalizations after heart failure diagnosis: a community perspective. J Am Coll Cardiol. 2009;54(18):1695–1702.

PMID 19850209 DOIObservational

Yancy CW. Heart failure in African Americans. Am J Cardiol. 2005;96(7B):3i–12i.

PMID 16196165 DOIReview

Breathett K, Liu WG, Allen LA, et al. African Americans are less likely to receive care by a cardiologist during an intensive care unit admission for heart failure. JACC Heart Fail. 2018;6(5):413–420.

PMID 29622165 DOIObservational

Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505–1535.

PMID 30039513 DOIGuideline

O'Connell JB. The economic burden of heart failure. Clin Cardiol. 2000;23(Suppl III):III-6–III-10.

PMID 10761830 DOIReview

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.